A Phase I Study of SIE-1 in Post-menopausal Women with Hormone Receptor-positive Early Breast Cancer

The primary objective of this study is to evaluate the efficacy of intervention in patients diagnosed with hormone receptor-positive early breast cancer in post-menopausal women. Establishing therapeutic outcomes in this specific demographic is clinically significant for determining long-term management strategies. There are no secondary objectives reported.

The study population consists of 63 female patients diagnosed with hormone receptor-positive early breast cancer. The participants are post-menopausal individuals within the specified age ranges of 3 and 4. The sponsor did not provide information regarding lifestyle considerations or specific selection methodologies.

This Phase 3 clinical trial is designed to evaluate interventions for hormone receptor-positive early breast cancer in post-menopausal women. The study follows a randomized, double-blind, controlled methodology. The clinical process begins with a screening visit to determine eligibility. Following enrollment, participants proceed through scheduled follow-up visits to monitor clinical outcomes and safety. The sequence concludes with an end-of-study visit. The total duration of participant involvement is determined by the protocol, with the study estimated to conclude by September 2028. Early termination from the study may occur based on predefined clinical criteria or safety requirements.

The clinical trial aims to evaluate the efficacy in patients diagnosed with hormone receptor-positive early breast cancer in post-menopausal women.